Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Triple-negative breast cancer (TNBC) is associated with a substantial economic burden on healthcare systems and societies and considerably reduced productivity and health-related quality of life for patients. This study synthesized the published literature on the economic and humanistic burden of TNBC. The estimates of mean per-patient annual direct medical costs ranged from around $20,000 to over $100,000 in stage I to III TNBC and from $100,000 to $300,000 in stage IV TNBC. Treatment with pembrolizumab or talazoparib showed significantly greater improvements in health-related quality of life compared with chemotherapy.